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Hepatocellular carcinoma (HCC) is an extremely aggressive form of liver cancer
with a low survival rate due to high recurrence. Increases in Rho-associated Protein
Kinase (ROCK) activity are correlated with a more aggressive, metastatic phenotype
associated with advanced HCC. Inhibitors for ROCK have shown potential for the
reduction of this metastatic phenotype of HCC. We outline the design and optimization of
a direct activity sensor for ROCK that utilizes a phosphorylation-sensitive sulfonamidooxine fluorophore, termed Sox, and is capable of reporting on the inhibition of ROCK.
This CSox-based activity probe utilizes chelation-enhanced fluorescence (ex. = 360 nm
and em. = 485 nm) between the proximal phosphorylated residue, Mg2+ and the Sox
fluorophore. This allows for the direct and continuous monitoring of phosphorylation of
the peptide-based probe over time. The sensitivity of the optimal CSox-based probe,
ROCK-S1, was detected to be 10 pM of recombinant enzyme. Using this probe we
demonstrate the ability to directly and rapidly assess a pilot small molecule library for
inhibitors of ROCK2, using a robotics platform. In a step towards applying our probe in
complex biological systems, we identify the optimal conditions for monitoring ROCK2
while inhibiting off-target enzymes (PKCα, PKA, and PAK). Our work provides a
sensitive assay platform for ROCK activity that is compatible to HTS and could
potentially be used to interrogate ROCK activity in heterogeneous biological samples.
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List of Abbreviations
CHEF

Chelation-Enhanced Fluorescence

CSox

Cysteine-Sox

DTT

Dithiothreitol

EGTA

Ethylene Glycol Tetraacetic Acid

HCC

Hepatocellular Carcinoma

HTS

High Throughput Screening

KD

Equilibrium Disassociation Constant

MLC

Myosin Light Chain

PBS

Phosphate-buffered saline

ROCK

Rho-associated Protein Kinase

Sox

Sulfonamido-oxine

IC50

Half Maximal Inhibitory Concentration
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Chapter 1- Introduction
1.1 Structural and mechanistic characteristics of protein kinases
Protein kinases are essential for the regulation of signaling pathways through
phosphorylation, a post-translational modification. Phosphorylation of protein kinases is
crucial for various cellular processes, including cell growth, cell motility, and apoptosis.1
Protein kinases accomplish this post-translational modification through the transfer of γphosphate from ATP to a serine, threonine, or tyrosine residue (Figure 1-1).2 However
the phosphorylation state of a protein kinase does not always correlate to activity levels.3
Other post-translational modifications have been shown to modify kinase activity.
Dysregulations of kinase activity can lead to, or be the result of, certain disease states.4
Protein kinase sensors that can directly and continually assess protein kinase activity are
needed for both monitoring aberrant activity and identifying true inhibitors of protein
kinases. 5 The ability to monitor kinase activity in real time will lead to an enhanced
understanding of the mechanisms of disease, as well as an increased ability to inhibit
specific aspects of disease states.
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Figure 1-1. Protein kinases catalyze the transfer of the γ-phosphate on ATP to the target
substrate.
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1.2 Current methodology for the detection of protein kinase activity
Currently, there are multiple techniques for indirectly or discontinuously probing
protein kinase activity. Many of these techniques utilize radioactivity, costly reagents, or
specialized equipment that can make implementation, on a large scale, cost prohibitive.
An ideal technique for assessing protein kinase activity would have the capability to
monitor the activity directly and continuously in a High Throughput Screening (HTS)
format. In addition, analytical probes capable of detecting kinase activity in
homogeneous biological samples would be desirable.
One common assay for the assessment of protein kinase activity is a radiometricbased assay that monitors the transfer of a radiolabelled γ-phosphate from ATP to the
substrate, making it broadly applicable to assessing kinase activity.6 The activity of the
protein kinase is then assessed through scintillation counting of the radiolabeled peptide
substrate. In this method the protein kinase activity is monitored indirectly,
discontinuously, and cannot be practically implemented in HTS. Radiolabelling ATP is
also not a compatible method for measuring kinase activity in cell lysates due to the large
number of cellular components and other kinases that utilize ATP.
A more specific approach to assessing protein kinase activity can be found with
immuno-based assays. The use of antibodies considerably increases the specificity of the
sensor, although also increases the cost. Western Blotting is one example of a common
antibody-based assessment of protein kinase activity. This method requires phosphospecific antibodies in order to probe the phosphorylation state of the protein kinase. In
some cases, these antibodies are not available or require the probing of a downstream
target of the kinase, such as in the case of ROCK. Western blotting is also indirect,
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discontinuous, and impractical for HTS. However this method can be used with cell
lysates and tissue homogenates.
Another approach to monitoring kinase activity that is utilized in HTS is immunofluorescent assays such as ALPHA Screen (Amplified Luminescence Proximity
Homogeneous Assay). 7 This immuno-fluorescent approach combines the strength of
luminescent small molecules with the specificity of antibodies to create sensors that are
able to be implemented in HTS and complex systems, such as cell lysates. ALPHA
Screen utilizes a specific GST-tagged peptide substrate for the target on a GSH coated
donor bead and acceptor bead coated with antibodies that recognize phosphorylation of
the peptide substrate. When the donor bead is excited at 680nm by a laser, a
photosensitizer, phthalocyanine, that is present in the donor beads produce singlet oxygen
molecules that react with thioxene derivatives and dyes contained in the acceptor beads.
This results in emission that can be measured between 520 and 620 nm. ALPHA Screen
is a direct activity assay that can be implemented in HTS but is discontinuous and
requires time points to be collected in order to obtain rates.
The Imperiali lab has previously reported multiple protein kinase sensors that
utilize chelation-enhanced fluorescence (CHEF) for direct and continuous reporting of
kinase activity. These sensors utilize a sulfonamido-oxine (Sox) fluorophore that is
bound to a specific peptide substrate through a modified amino acid, cysteine. This
modified amino acid is placed in the +2 or -2 position of the site of phosphorylation for
the Mg2+ binding site to be in an optimal configuration (Figure 1-2). The phosphorylation
of the Sox sensor leads to an increase in affinity for Mg2+. This sensing modality utilizes
CHEF between the phosphorylated residue on the specific peptide substrate, Mg2+, and
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the Sox fluorophore. The non-phosphorylated peptide sensor has relatively weak Mg2+
binding (100 mM <KD< 300 mM), compared to the affinity of Mg2+ for the
phosphorylated peptide sensor (4 mM <KD <20 mM). The increase of fluorescence over
time correlates to the rate of phosphorylation of the probe by the protein kinase. 8

7

Figure 1-2. A modified amino acid, CSox, is integrated into a known peptide substrate
for a target kinase. After phosphorylation of the peptide substrate, CHEF between Mg2+,
Sox, and the phosphorylated residue can be monitored using 360 nm excitation and 485
nm emission.
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Unlike some of the previously described assay formats, Sox sensors are able to
produce robust fluorescence increases in the presence of physiologically relevant
concentrations of Mg2+ (0.5-5 mM)9 and ATP (0.8-1 mM).10,11 Upon phosphorylation, the
sensors can exhibit a 2—10 fold increase in fluorescence. The Sox sensors are also
capable of HTS and measuring the activity of a kinase of interest in cell lysates. 12,13,14,15
This format also causes minimal interference of substrate binding and kinase activity.
The Dalby laboratory has utilized the Sox sensors for HTS to discover novel inhibitors of
eEF-2K using a 32,960 compound library. The IC50 was determined for the top 2
compounds using a Sox sensor and found to be in the micro-molar range, which was
confirmed by radiometric and luminescence assays.16
1.3 The protein kinase ROCK drives aggressive phenotypes in HCC
Hepatocellular Carcinoma (HCC) is a highly aggressive and the most common
form of liver cancer which can be caused from anabolic steroids, aflatoxins, alcohol,
cirrhosis, hemochromatosis, Hepatitis A, and Hepatitis B. 17 In addition, HCC is the third
leading cause of death from cancer and has a bleak, five-year survival rate of 15%. The
low survival rate has multiple contributing factors but is primarily due to the recurrence
of the cancer after treatment (Figure 1-3).18 Intrahepatic metastasis is one type of
recurrence of HCC and is associated with progression to more aggressive phenotypes.
Despite our knowledge of genetic mutations associated with HCC, there is relatively little
known about the molecular mechanisms that drive this disease at the biochemical level.19
Nonetheless, one possible route to treatment of advanced disease would be inhibition of
the molecules responsible for metastatic HCC. Such treatment could, potentially, increase
survival rate.

9

Figure 1-3. Hepatocellular carcinoma can be brought on by many factors and has a very
low survival rate due to the high probability of recurrence. Intrahepatic metastasis is
thought to proceed via the portal vein, as shown.
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Cancer metastasis involves multiple steps each of which are potential targets for
therapeutic intervention. 20 These steps include primary malignance, cellular detachment,
dissemination, and finally proliferation as new tumors. In the case of intrahepatic
metastasis, it is suggested that the process of dissemination occurs via the portal vein, and
the proliferation of new tumors is localized to the initial environment of the cancer
(Figure 1-3).21 Due to the localization of the metastasis, the initial step of cellular
detachment and cell motility has been identified as a target for potential inhibition.
Therefore, significant efforts have been undertaken to identify signaling molecules that
regulate the metastatic potential of HCC.
Evidence as to the role of ROCK in HCC has been growing. Two HCC cell lines
were found to produce intrahepatic metastasis in mice, Li7 and KYN-2.19 These cell lines
also exhibited increased cell motility. The increased cell motility in both cell lines was
found to be reduced with C3 exoenzyme, a known specific Rho inhibitor. Li7 was also
stably transfected to have a defective mutant without ROCK. This newly transfected
knockdown cell line had a drastically decreased percentage of motile cells. These data
suggest that ROCK might mediate cell motility, at least in this cell line. In KYN-2 a cell
transfectant without ROCK was not able to be established. This adds to the evidence that
ROCK might be responsible for cell proliferation, especially in this cell line.
1.2 Biology of ROCK
ROCK has been identified as a critical regulator of cell motility and metastatic
potential in HCC.22 ROCK is a serine/threonine protein kinase that is a member of the
AGC family. ROCK1 and ROCK2 are two isoforms that comprise the ROCK family and
have 89% homology of the kinase domain.23 Both isoforms of ROCK consist of an N-
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terminus kinase domain, which includes the activation loop and threonine
phosphorylation site (Figure 1-4). Following the kinase domain is the coiled coil region
that contains the Rho-binding domain. 24 This induces activation when Rho-GTP is
bound. The structure of ROCK also includes a pleckstrin homology domain that contains
a cysteine rich region.

12

Figure 1-4. Kinase domain of ROCK2 with labelled activation loop and T240
phosphorylation site shown.25,26
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ROCK is able to induce cell motility through the phosphorylation of multiple
downstream targets. ROCK phosphorylates the regulatory subunit of the myosin light
chain (MLC) and deactivates myosin-binding subunit of myosin light chain
phosphatase.27 This in turn leads to increased actomyosin-based contractility. ROCK also
phosphorylates LIM kinases, including LIMK1, which leads to actin filament
stabilization.28 Through these three pathways, ROCK utilizes phosphorylation to activate
downstream targets in order to induce cell motility (Figure 1-5).
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Figure 1-5. The pathway of ROCK2 that leads to productive cell motility through both
actomyosin-based contractility and actin filament stabilization.
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1.5 The need for a ROCK probe
Beyond inhibitors, there is also a general need for a ROCK activity sensor.
Current means of assessing ROCK activity fall short for the direct and continuous
measurement. ROCK is activated through the binding of Rho-GTP and a conformational
change to free the catalytic domain (Figure 1-6). The phosphorylation state of the kinase
does not directly equate to the activity, therefore negating probing the phosphorylation
state as a viable option for assessing the activity. Using a Western Blot to monitor the
activity of ROCK in complex biological systems requires probing a downstream kinase’s
phosphorylation state. This method does not directly show ROCK activity, rather an
indirect proxy for ROCK activity. There is a current need for a means to directly assess
ROCK activity, such as with the direct and continuous CSox-based activity sensor.

16

Figure 1-6. Rho-GTP binding induces a conformational change that activates ROCK2.
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Chapter 2 – Design and Optimization of CSox-Based Sensor
for Rho-Associated Protein Kinase and Implementation in
High Throughput Screening
2.1 Introduction
The entirety of this paper entitled “A real-time, fluorescence-based assay for Rhoassociated protein kinase activity” is presented in Appendix A.
As previously discussed, there is a desperate need for an activity sensor that is
capable of directly and continuously monitoring the activity of ROCK in HTS. The goal
of this work is to design and optimize such a sensor and identify novel inhibitor
compounds of ROCK.
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2.2 Results and discussion
2.2.1 Rational design and characterization of preliminary ROCK activity probes
In order to design a CSox-based activity sensor for ROCK, we first sought to
identify viable peptide substrates to build upon. The Katayama lab screened 136 peptide
substrates against ROCK2 using a radiolabel assay to determine the ability of ROCK2 to
phosphorylate the substrates. These peptide substrates are derived from multiple kinases,
including LIMK1, MLC, and MBS of MLC phosphatase. From these substrates, we
identified one that had a low KM and minimal off target binding, R22. R22 was derived
from LIMK1 with a KM of 1.9 µM.29 From this information and the preliminary KM from
the peptide, we hypothesized that we would be able to design a Sox sensor that is highly
sensitive with µM affinity.
Using the R22 sequence, we synthesized two CSox-based activity sensors with
CSox in the +2 and -2 position from the site of phosphorylation. These were termed
ROCK-S1 and ROCK-S2 (Table 2-1). Previous research has shown that varying the site
of CSox can drastically alter the affinity of the sensor. 11,30 For positive controls, we also
synthesized the same sensors, but with phospho-threonine at the site of phosphorylation
instead of threonine, ROCK-P1 and ROCK-P2 (Table 2-1).
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Name

Sequence

ROCK-S1
KPARKKRYTV-CSox-GNPYWM
ROCK-P1
KPARKKRYpTV-CSox-GNPYWM
ROCK-S2
KPARKK-CSox-YTVVGNPYWM
ROCK-P2
KPARKK-CSox-YpTVVGNPYWM
Table 2-1. Sequences of ROCK Activity probes and Mg2+ KD values.

Mg2+ KD (mM)
420
17
66
7.1
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In order to determine the optimal Mg2+ concentrations for ROCK-S1 and ROCKS2, we measured both the control and experimental sensors with varying concentrations
of Mg2+. We expect the control sequences to exhibit a stronger affinity for Mg2+ because
of their phosphorylation state (Figure 2-1). However, it is of importance to quantify the
differences in Mg2+ affinities between sequences in order to properly control the
concentration of Mg2+. 31 Previous work from our laboratory has shown that this
optimization is extremely important because of the dramatic improvement in assay
performance.30 After determining the KD of Mg2+ and the sensor, we measured the fold
fluorescence increase of each pair of control/experimental sensors by varying both Mg2+
and ATP concentrations (Table 2-2). We were able to observe the maximal fluorescence
enhancements with 0.1 mM ATP. Previous work has demonstrated that the KM of
ROCK2 for ATP is 1.4µM, indicating that 0.1mM ATP could be used for enzymatic
essays without severely interfering with the rate of substrate phosphorylation. 32
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Figure 2-1. Fluorescence of ROCK-P1 (A), ROCK-S1 (B), ROCK-P2 (C), and ROCKS2 (D) as a function of Mg2+ concentration.
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Fold Fluorescence Enhancements
0.1 mM
Mg2+ (mM)
1.0 mM ATP
Peptide
ATP
10
2.7
2.1
20
2.5
2.0
ROCK-P1
40
2.0
1.8
3.5
4.9
3.5
7.0
6.1
6.0
ROCK-P2
10.5
7.0
6.5
Table 2-2. Fold fluorescence enhancements of ROCK-S1 and ROCK-S2 as a function of
Mg2+ and ATP concentrations. Fold fluorescence enhancement values were calculated by
dividing the fluorescence of the phosphorylated positive control peptide by the
fluorescence of the non-phosphorylated peptide.
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2.2.2 Evaluation of probe efficiency for ROCK2
To establish the probe efficiency for ROCK2, we measured to rate of product
formation with varied concentrations of each probe. These experiments were carried out
using the optimal Mg2+ and ATP concentrations that were previously determined. In
these experiments we observed substrate inhibition for both probes at increasing
concentrations. This finding exemplifies why full characterization is needed for CSoxbased activity probes. At >10 µM concentrations, the assay performance would be
increasingly diminished. We were able to determine the KM, kcat and kcat/KM from the
assays which allowed us to determine the optimal sensor (Figure 2-2). By comparing the
kcat/KM values for each probe, ROCK-S1 and ROCK-S2, we determined ROCK-S1 was
188-fold more efficient for ROCK2 (Table 2-3). ROCK-S2 has a 33 fold decrease in
probe turnover by placing the CSox at the -2 position relative to the site of
phosphorylation. Using the previous findings, we determined the optimal assay
conditions and chose to employ ROCK-S1 at a concentration of 5 µM for all subsequent
experiments.

24

Figure 2-2. Kinetic parameters for ROCK-S1 (A) and ROCK-S2 (B) with ROCK2 (1
nM). Data was fit using Eq. 2.
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Peptide

kcat/KM

ROCK-S1

6.37 x 106 M-1 s-1

ROCK-S2

3.39 x 104 M-1 s-1

Table 2-3. kcat/KM values for each sensor construct for the determination of the optimal
sensor.
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2.2.3 ROCK-S1 limit of detection for ROCK2
When optimizing a sensor, high sensitivity and high reproducibility of the sensor
is ideal. This is especially important for assays that will be employed in HTS. We
measured the phosphorylation of our probe, ROCK-S1, in the presence of decreasing
amounts of ROCK2 to determine the sensitivity of the probe. Based on the data collected
from these experiments, we calculated the limit of detection of ROCK-S1 with ROCK2
to be as low as 10 pM (Figure 2-3). This was determined based on the trend line,
y = 701.7x – 4.1 (R2 = 0.9991), where y is the average reaction slope in AFU/min and x
is the concentration of ROCK2 in nM. These experiments were also determined to be
highly reproducible (Z’-factor = 0.6 at 0.1 nM ROCK2), which further confirmed that
these probes can be utilized in HTS. 33
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Figure 2-3. ROCK-S1 (5 μM) phosphorylation as a function of ROCK2 concentration.

28

2.2.4 ROCK-S1 can report on ROCK2 inhibition
We wanted to determine if ROCK-S1 could monitor the inhibition of ROCK2 in
the presence of a known and well characterized ATP-competitive inhibitor,
GSK429286.34 Our results showed a concentration dependent decrease in activity that is
consistent with our expectations (Figure 2-4). Our experimental IC50 was consistent with
the literature reported IC50 value of 63 nM.35 These results indicate that ROCK-S1 is
capable of directly monitoring ROCK2 inhibition in a HTS format using a 384-well
plates.
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Figure 2-4. ROCK-S1 is able to monitor the inhibition of ROCK2 and produce results
consistent with literature values.
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2.2.5 Optimization of HTS conditions
Our goal was to implement our CSox-based activity sensor in a HTS to identify
novel inhibitors of ROCK2. We chose a 78 compound library of known kinase inhibitors
(Table 2-4). We expected six compounds to inhibit ROCK2 in this library. The five
known ROCK2 inhibitors are fasudil36, Y2763237, HA110038, H8930, and GW507439, in
addition to the broad spectrum inhibitor Ro318220.40 To perform a high throughput
screen, we used an automated robotics assay platform to monitor the inhibition of
ROCK2 with ROCK-S1 with 10 µM of each compound in quadruplicate 384-well plate
assays. In addition to the five known inhibitors, we also observed >50% inhibition in the
presence of two other inhibitors. PHA66575241 and IKK1642 have not been, to the best of
our knowledge, identified as ROCK2 inhibitors in primary literature (Figure 2-5). To
measure the effectiveness of each novel inhibitor, we obtained IC50 value for both
PHA665752 and IKK16 (Figure 2-6). We found that these novel inhibitors had low μM
to high nM potency for ROCK2 in the presence of 0.1 mM ATP. Characterizing the
known inhibitors of ROCK2 has the potential of eliminating off target inhibition. This off
target activity has the potential to skew results, especially in cell-based assays that utilize
high concentrations of inhibitors. In the future, these optimized condition could be used
to screen a larger inhibitor library or fragment libraries for novel ROCK2 inhibitor
scaffolds.
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Identifier

Inhibitor (10 μM)

% Inhibition

Std. Dev.
(%)

A1

GSK 429286

100

0.12

A2

ML 9

22

0.82

A3

NH 124

11

0.49

A4

Fasudil

66

0.39

A5

GF109203x

31

1.00

A6

Genistein

4

0.26

A7

LY294002

3

0.63

A8

U0126

3

0.33

A9

PD98059

3

0.30

A10

Y-27632

80

0.22

B1

No Inhibitor Control

-1

1.12

B2

Olomoucine

16

0.83

B3

LFM-A13

14

0.62

B4

ZM 336372

10

0.60

B5

ZM 449829

7

0.20

B6

ZM 39923

9

0.55

B7

GW 5074

52

2.26

B8

PP1

5

0.36

B9

SB 203580

12

0.18

B10

(-)-Tarreic acid

8

0.36

C1

PP 2

22

1.82

32

C2

SU 4312

21

1.25

C3

SP 600125

3

2.90

C4

Purvalanol A

13

0.49

C5

Purvanol B

16

0.47

C6

KU 55933

8

0.37

C7

AG 490

28

1.42

C8

SB 216763

8

0.58

C9

SB 415286

14

0.46

C10

Arctigenin

7

0.70

D1

NSC 693868

28

2.14

D2

SB 239063

21

1.24

D3

SL 327

21

1.70

D4

Ro 31-8220

55

0.97

D5

Aminopurvalanol A

21

1.29

D6

API-2

11

0.85

D7

GW 441756

17

1.38

D8

GW 583340

22

0.92

D9

Ro 08-2750

44

0.59

D10

TBB

11

0.09

E1

Hexabromocyclohexane

21

1.32

E2

HA 1100

68

0.37

E3

BIBX 1382

23

1.06

E4

CGP 53353

15

1.36

33

E5

Arcyriaflavin A

-9

1.02

E6

ZM 447439

20

0.86

E7

ER 27319

15

0.35

E8

ZM 323881

12

0.89

E9

ZM 306416

11

0.24

E10

IKK 16

81

0.87

F1

Ki 8751

24

1.39

F2

10-DEBC

21

0.79

F3

TPCA-1

22

0.53

F4

SB 218078

-26

6.40

F5

SB 202190

18

1.37

F6

PD 198306

13

0.67

F7

Ryuvidine

31

1.34

F8

IMD 0354

14

0.67

F9

CGK 733

11

0.20

F10

PHA 665752

85

0.85

G1

PD 407824

18

1.60

G2

LY 364974

17

1.08

G3

CGP 57380

16

1.21

G4

PQ 401

14

1.38

G5

PI 828

13

1.15

G6

NU 7026

12

0.90

G7

D4476

-23

5.10

34

G8

EO 1428

10

1.18

G9

H 89

76

1.28

G10

FPA 124

9

0.88

H1

GWn843682X

14

2.22

H2

Iressa

15

2.03

H3

SU 5416

10

1.73

H4

1-Napthyl PP1

8

1.81

H5

GSK 650394

19

2.23

H6

BIO

5

1.66

H7

SD 208

11

1.10

H8

Compound 401

6

1.28

H9

BI 78D3

8

1.21

H10

SC 514

8

1.05

Table 2-4. Complete list of inhibitors in the library used for HTS.
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Figure 2-5. Proof-of-principle HTS for ROCK2 inhibitors. (A) compounds (10 μM) were
assayed against ROCK2 (1 nM) in the presence of 1 mM ATP. Percent inhibition was
calculated from quadruplicate assays. A complete compound list in given in Table 2-4.
Position A1 is 10 μM GSK429286 and position B1 is no inhibitor. (B) Eight compounds
displayed >50% ROCK2 inhibition. Six have been previously reported as ROCK2
inhibitors (grey bars) while three have not been previously reported to inhibit ROCK2 to
the best of our knowledge (red bars).
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Figure 2-6. ROCK-S1 was used to monitor the inhibition of ROCK2 (5 µM) by
PHA665752 and IKK16 (0.25 nM). Both inhibitors display low μM to high nM inhibition
of ROCK2, respectively.
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2.2.6 Selectivity of ROCK-S1
An important advantage that CSox-based activity sensors has over other current
means of assessing kinase activity, is the ability to monitor the activity of a target kinase
in complex biological samples, such as cell lysates and tissue homogenates. 12,13,14,15 In
complex systems, there is the possibility of off-target activity on the sensor from other
enzymes with similar consensus motifs. To remedy this, inhibitors for the off-target
enzymes have been used to reduce the potential false positive signal in CSox-based
assays.43,44,31,14 Based on consensus motifs, we identified potential kinases that might
present off target activity in complex biological systems.45,46 We monitored the activity
of ROCK2, ROCK1, PKCα, PKA, and PAK with ROCK-S1. The results indicated
ROCK-S1 is phosphorylated by two off target enzymes from this panel, PKA and PKCα
(Figure 2-7).
Based on this information, we wanted to determine if PKA and PKCα activity
could be inhibited while maintaining ROCK activity. To accomplish this, we identified
well-characterized PKA and PKCα inhibitors to utilize, including PKItide, PKC inhibitor
peptide, calmidazolium and GF109203X. 43 Using the inhibitor cocktail described, we
were able to preserve 58% of the activity of ROCK2 (Figure 2-8). Our panel does not
contain all off-target enzyme possibilities in cell lysates, however; this work is a good
first step in determining conditions for the analysis of ROCK activity in vitro.
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Figure 2-7. Selectivity for ROCK-S1. (A) The phosphorylation of ROCK-S1 (5 μM) in
the presence of the indicated enzyme (10 nM). (B) The same as panel A except the offtarget inhibitors PKItide (0.4 μM), PKC inhibitor peptide (4 μM), GF109203X (5 μM),
and calmidazolium (4 μM) are included.
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Figure 2-8. A significant proportion (58%) of ROCK2 activity is retained in the presence
(+) of the inhibitor cocktail (0.4 μM PKItide, 4 μM PKC inhibitor peptide, 5 μM
GF109203X, and 4 μM calmidazolium) compared to reactions performed without
inhibitors (-).
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2.3 Experimental
2.3.1 General reagents, instrumentation, and procedures
Fluorescence assays were conducted using a BioTek SynergyH2 microplate reader.
Assays were excited at 360 nm and the emission was recorded at 485 nm. Reactions were
incubated at 30° C during fluorescence analysis. The plates used for fluorescence assays
were either 384-well or 96-well half area plates (Corning: 3824 or 3992 respectively).
The total volume for assays was 40 µL (384-well plates) or 120 µL (96-well plates). All
assays were conducted in triplicate unless otherwise noted.
2.3.2 Peptide synthesis
Peptides were synthesized as previously described.31 The peptides were purified using
preparative reverse-phase HPLC and peptide identity was confirmed using ESI-MS
(Table 2-5). To determine peptide concentration, the absorbance of each construct was
measured and concentrations were calculated using the molar absorptivity of Sox, 8247
M-1 cm-1 at 355 nm in 1 mM Na2EDTA and 0.1 M NaOH.8
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Calculated Mass Observed Mass
[M+xH]x+
[M+xH]x+
Peptide
2+
1202.7
ROCK-S1 [M+2H] : 1202.9
1243.5
ROCK-P1 [M+2H]2+: 1243.0
2+
1173.9
ROCK-S2 [M+2H] : 1173.6
1213.9
ROCK-P2 [M+2H]2+: 1213.5
Table 2-5. ESI-MS data for ROCK sensors.
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2.3.3 Determination of Mg2+ affinity and fold fluorescence increase
Stock solutions of Mg2+ were prepared from Alfa Aesar Puratronic grade MgCl2
salt and standardized by titration with EDTA in the presence of Eriochrome Black T. The
Mg2+ KD was determined by measuring the fluorescence of each construct in the presence
of 0.5, 1, 5, 10, 50, and 75 mM MgCl2 in a buffer containing 50 mM Tris-HCl (pH = 7.5
at 22° C) and 150 mM NaCl. Peptide was added to each assay at a final concentration of
1 mM. Fluorescence intensity was plotted and fit to a single site binding isotherm using
Kaleidagraph to determine the KD by fitting to Eq. (1).
𝑒𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝑎𝑡 485𝑛𝑚 = (𝐵𝑚𝑎𝑥 ∗ [𝑀𝑔2+ ])/(𝐾𝐷 + [𝑀𝑔2+ ]) (1)
Where Bmax is the maximum specific binding in arbitrary fluorescence units and [Mg2+]
is the concentration of Mg2+ in mM.
The fold fluorescence increase of phospho- versus nonphosphosensors was performed for
each set of peptides. The Mg2+ concentrations used for each set of constructs were chosen
based on the KD of the corresponding phospho-peptide. For each concentration of Mg2+,
two concentrations of ATP were investigated (0.1 mM and 1 mM).
2.3.4 Recombinant enzyme assays
Recombinant ROCK2 (Life Technologies, PV3759), was diluted in enzyme
dilution buffer: 50 mM Tris-HCl (pH = 7.5 at 22°C), 1 mM EGTA, 0.01% Brij (v/v), and
10% glycerol (v/v). Kinase assays were conducted in a buffer containing: 50 mM TrisHCl (pH = 7.5 at 22° C), 0.1 mM ATP, 1 mM EGTA, 2 mM DTT, 0.01% Brij (v/v), and
the optimal Mg2+ concentration for each sensor. Assays were equilibrated to 30° C for 20
min before the addition of recombinant enzyme. Reaction velocities were determined by
correcting for the loss of substrate fluorescence as previously described.8 Kinetic
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parameters were determined by plotting reaction velocities as a function of substrate
concentration and fitting to Eq. (2) in Kaleidagraph.47
𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 = (𝑉𝑚𝑎𝑥 ∗ [𝑆])/(𝐾𝑀 + [𝑆] + (

[𝑆]2
𝐾𝑆

)) (2)

Where Vmax is the maximum velocity, [S] is the concentration of substrate in µM, KM is
the Michaelis-Menten constant, and KS is the dissociation constant for substrate
inhibition.
The limit of detection for the assay was defined as the smallest concentration
ROCK2 that produced a signal that was three standard deviations above assay noise level.
Enzymes used in the panel assay were purchased through Life Technologies and diluted
in enzyme dilution buffer. Where indicated the following inhibitor cocktail was added to
the panel assays: PKItide (0.4 mM), PKC inhibitor peptide (4 mM), GF109203X (5 mM),
and calmidazolium (4 mM).43
2.3.5 High-throughput screening
Inhibitors were purchased from Tocris (3514) and supplied at 10 mM in DMSO.
Inhibitors were diluted with PBS to a working concentration of 1 mM prior to screening.
HTS assays were conducted using a robotics platform to prepare quadruplicate wells
containing 1 nM ROCK2, 5 mM ROCK-S1, 1 mM ATP, 10 mM MgCl2, 50 mM TrisHCl (pH = 7.5 at 22°C), 1 mM EGTA, 2 mM DTT, 0.01% Brij (v/v), and 10 mM of the
indicated inhibitor. The final concentration of 10 mM inhibitor was chosen in order to
identify potential weak inhibitors. Wells with 10 mM GSK429286, no inhibitor, or no
inhibitor and no enzyme were used as controls. Assays were performed in 384-well
plates. Reaction slopes for each inhibitor were averaged and percent inhibition was
calculated by comparison to controls. Two compounds from the initial 80 compound
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commercial library (TCS359 and SB431542) are not included in the final data analysis
due to extremely high autofluorescence, at a concentration of 10 mM, which resulted in
detector overload. We did not observe any effect from DMSO on the rate of
phosphorylation in these assays. Reaction slopes were determined using the initial linear
regions of fluorescence data; fits contained at least 15 points.
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2.4 Conclusions and Future Directions
This work has focused on the design and optimization of a CSox-based ROCK
sensor that can be utilized in HTS for novel inhibitor discovery. We have shown that this
probe is capable of directly monitoring ROCK2 activity as well as ROCK2 inhibition.
Through the work with HTS in a 384-well plate format using an automated robotics
system, we have established the feasibility of implementing this system with larger
inhibitor libraries. We have also begun to establish the optimal conditions for monitoring
ROCK2 monitoring in complex biological systems through the utilization of an inhibitor
cocktail that retains ROCK activity. In the future, ROCK-S1 will be employed to identify
novel inhibitors of ROCK and interrogate ROCK activity perturbations in HCC.
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Appendix A
A real-time, fluorescence-based assay for Rho-associated protein
kinase activity
Reproduced with permission from:
M.I. Kelly, T.J. Bechtel, D.R. Reddy, E.D. Hankore, J.R. Beck, C.I. Stains. A real-time,
fluorescence-based assay for Rho-associated protein kinase activity. Anal. Chim. Acta.
891, 284-290. (2015)
(doi: 10.1016/j.aca.2015.07.058)
Copyright 2015 Elsevier B.V.
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1. Introduction
The ﬁve-year survival rate for HCC is 15% [1], due in large part to
the aggressive nature of the disease when diagnosed in the clinic.
As a consequence, signiﬁcant efforts are needed to both enhance
early detection and develop approaches for inhibiting the metastatic phenotype of HCC. Towards the latter goal, protein kinases
represent attractive candidates for inhibitor development [2e4]
and subsequent clinical intervention [5e8]. Previous work has
shed light on the signaling molecules responsible for the invasive
phenotype observed in HCC [9,10]. As a result of this work, ROCK
has emerged as a potential target for inhibiting metastasis in HCC.
ROCK1 and ROCK2 were originally identiﬁed as selective RhoA-GTP
interacting proteins [11e13] and share 89% homology between
their respective kinase domains [14]. ROCK couples Rho activation
with contractile force generation through the direct phosphorylation of LIM kinases [15,16], the regulatory subunit of the myosin
light chain [17,18], and the myosin-binding subunit of myosin light
chain phosphatase [17]. Together these phosphorylation events
lead to productive cell movement [19]. Interestingly, two HCC cell
lines (Li7 and KYN-2) were found to have increased cell motility
in vitro that could be blocked using C3 exoenzyme, a Rho inhibitor
[9]. Stable transfection of a dominant negative form of ROCK into
these cell lines also decreased cell motility and metastatic rate
in vivo compared to the parent cell lines. In addition, a small
molecule inhibitor of ROCK activity, Y27632 [20], signiﬁcantly
impaired the ability of Li7 cells to form metastatic nodules in mice
[10]. Overall, this work adds to the growing evidence that ROCK
activity is necessary for the metastatic phenotype observed in HCC
and that ROCK inhibitors could provide a means for interfering with
the progression of HCC in the clinic.
In general, current protein kinase activity assays rely on the use
of radioactivity or high-cost reagents and/or instrumentation
[21,22]. A variety of assay formats have been described that
leverage the speciﬁcity and sensitivity of antibody-based reagents
[23e25]. These techniques represent powerful approaches to
monitoring kinase activity; however, the costs of these assay formats, and in certain cases the necessity of specialized equipment,
can hinder their application in HTS. Alternatively, peptide-based
kinase activity probes, capable of producing a change in ﬂuorescence signal upon phosphorylation, can provide a straightforward,
low-cost alternative for HTS [26e33]. As one example, the Imperiali
laboratory has recently described the use of the phosphorylationsensitive Sox ﬂuorophore as a general platform for the design of
sensitive serine/threonine and tyrosine kinase activity sensors
[28,29,34,35]. These Sox probes detect phosphorylation of a proximal residue through CHEF upon binding of Mg2þ. However, initial
Sox-based probe designs required deletion of sequences either Nor C-terminal to the phosphorylation site in order to install a b-turn
to allow for productive CHEF. To address this issue, a second generation probe design was envisioned in which a cysteine derivative,
termed CSox, could be substituted for a native amino acid proximal
to the site of phosphorylation [36]. These second generation CSoxbased sensors allow for productive CHEF while necessitating only a
single amino acid substitution in a peptide substrate (Fig. 1). As a
consequence, CSox-based probes display tighter KM values for their
target kinases, allowing for the use of reduced sensor concentrations in assays [37e40]. CSox-based probes for protein kinase activity can be rapidly constructed using standard solid-phase
peptide synthesis and can provide a direct, real-time readout of
kinase enzymatic activity [41]. Moreover, the Dalby laboratory has
recently demonstrated the use of CSox-based probes to identify
inhibitors of eEF-2 from a HTS screen using 32,960 compounds [30].
This work demonstrates that CSox-based probes can reduce the
false positive rate associated with autoﬂuorescence of inhibitors in

Fig. 1. A single amino acid in a peptide substrate is replaced with CSox (left). Phosphorylation of an adjacent amino acid leads to CHEF, which can be quantiﬁed by
excitation at 360 nm and monitoring emission at 485 nm (right). The increase in
ﬂuorescence over time is proportional to kinase enzymatic activity.

HTS, since ﬂuorescence changes are monitored over time as
opposed to endpoint assays. The goal of the current work was to
determine whether CSox could be employed to construct a sensitive and robust sensor for ROCK enzymatic activity, with the long
term goal of utilizing this probe to discover novel ROCK inhibitors
as well as interrogate ROCK activity in human disease states.
2. Experimental
2.1. General reagents, instrumentation, and procedures
Fluorescence assays were conducted using a BioTek SynergyH2
microplate reader. Assays were excited at 360 nm and the emission
was recorded at 485 nm. Reactions were incubated at 30  C during
ﬂuorescence analysis. The plates used for ﬂuorescence assays were
either 384-well or 96-well half area plates (Corning: 3824 or 3992
respectively). The total volume for assays was 40 mL (384-well
plates) or 120 mL (96-well plates). All assays were conducted in
triplicate unless otherwise noted.
2.2. Peptide synthesis
Peptides were synthesized as previously described [41]. The
peptides were puriﬁed using preparative reverse-phase HPLC and
peptide identity was conﬁrmed using ESI-MS (Table S1). To determine peptide concentration, the absorbance of each construct was
measured and concentrations were calculated using the molar
absorptivity of Sox, 8247 M1 cm1 at 355 nm in 1 mM Na2EDTA
and 0.1 M NaOH [34].
2.3. Determination of Mg2þ afﬁnity and fold ﬂuorescence increase
Stock solutions of Mg2þ were prepared from Alfa Aesar Puratronic grade MgCl2 salt and standardized by titration with EDTA in
the presence of Eriochrome Black T. The Mg2þ KD was determined
by measuring the ﬂuorescence of each construct in the presence of
0.5, 1, 5, 10, 50, and 75 mM MgCl2 in a buffer containing 50 mM

TriseHCl (pH ¼ 7.5 at 22 C) and 150 mM NaCl. Peptide was added
to each assay at a ﬁnal concentration of 1 mM. Fluorescence intensity was plotted and ﬁt to a single site binding isotherm using
Kaleidagraph to determine the KD by ﬁtting to Eq. (1).

i.
i

h
h
KD þ Mg2þ
emission at 485 nm ¼ Bmax * Mg2þ

(1)

where Bmax is the maximum speciﬁc binding in arbitrary ﬂuorescence units and [Mg2þ] is the concentration of Mg2þ.
The fold ﬂuorescence increase of phospho- versus nonphosphosensors was performed for each set of peptides. The Mg2þ
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concentrations used for each set of constructs were chosen based
on the KD of the corresponding phospho-peptide. For each concentration of Mg2þ, two concentrations of ATP were investigated
(0.1 mM and 1 mM).
2.4. Recombinant enzyme assays
Recombinant ROCK2 (Life Technologies, PV3759), was diluted in

enzyme dilution buffer: 50 mM TriseHCl (pH ¼ 7.5 at 22 C), 1 mM
EGTA, 0.01% Brij (v/v), and 10% glycerol (v/v). Kinase assays were
conducted in a buffer containing: 50 mM TriseHCl (pH ¼ 7.5 at

22 C), 0.1 mM ATP, 1 mM EGTA, 2 mM DTT, 0.01% Brij (v/v), and the
optimal Mg2þconcentration for each sensor. Assays were equilibrated to 30  C for 20 min before the addition of recombinant
enzyme. Reaction velocities were determined by correcting for the
loss of substrate ﬂuorescence as previously described [34]. Kinetic
parameters were determined by plotting reaction velocities as a
function of substrate concentration and ﬁtting to Eq. (2) in Kaleidagraph [42].

velocity ¼ ðVmax *½SÞ=ðKM þ ½S þ ð½S2 =KS ÞÞ

(2)

where Vmax is the maximum velocity, [S] is the concentration of
substrate, KM is the MichaeliseMenten constant, and KS is the
dissociation constant for substrate inhibition. The limit of detection
for the assay was deﬁned as the smallest concentration ROCK2 that
produced a signal that was three standard deviations above assay
noise.
Enzymes used in the panel assay were purchased through Life
Technologies and diluted in enzyme dilution buffer. Where indicated the following inhibitor cocktail was added to the panel assays: PKItide (0.4 mM), PKC inhibitor peptide (4 mM), GF109203X
(5 mM), and calmidazolium (4 mM) [35].
2.5. High-throughput screening
Inhibitors were purchased from Tocris (3514) and supplied at
10 mM in DMSO. Inhibitors were diluted with PBS to a working
concentration of 1 mM prior to screening. HTS assays were conducted using a robotics platform to prepare quadruplicate wells
containing 1 nM ROCK2, 5 mM ROCK-S1, 1 mM ATP, 10 mM MgCl2,

50 mM TriseHCl (pH ¼ 7.5 at 22 C), 1 mM EGTA, 2 mM DTT, 0.01%
Brij (v/v), and 10 mM of the indicated inhibitor. The ﬁnal concentration of 10 mM inhibitor was chosen in order to identify potential
weak inhibitors. Wells with 10 mM GSK429286, no inhibitor, or no
inhibitor and no enzyme were used as controls. Assays were performed in 384-well plates. Reaction slopes for each inhibitor were
averaged and percent inhibition was calculated by comparison to
controls. Two compounds from the initial 80 compound commercial library (TCS359 and SB431542) are not included in the ﬁnal data
analysis due to extremely high autoﬂuorescence, at a concentration
of 10 mM, which resulted in detector overload. We did not observe
any effect from DMSO on the rate of phosphorylation in these assays. Reaction slopes were determined using the initial linear regions of ﬂuorescence data; ﬁts contained at least 15 points.
3. Results and discussion
3.1. Rational design and characterization of preliminary ROCK
activity probes
As a ﬁrst step towards the development of a CSox-based ROCK
activity sensor we set out to identify optimal peptide substrates for
ROCK. Recent work from the Katayama laboratory has examined
the ability of ROCK2 to phosphorylate a library of 136 peptides [43].

From this work, a sequence dubbed R22 was identiﬁed with a KM of
1.9 mM. We hypothesized that this sequence could be employed to
generate a CSox-based chemosensor with low mM afﬁnity for
ROCK2 in order to allow for minimal sensor usage during HTS.
Accordingly, we synthesized two CSox-based activity probes using
R22 as the template sequence with CSox placed at the þ2 and 2
positions relative to the site of phosphorylation, ROCK-S1 and
ROCK-S2 (Table 1). These two probe sequences represent important
steps in sensor optimization, as previous work has demonstrated
that the positioning of CSox in a peptide substrate sequence can
dramatically alter the sensitivity of probe constructs [36,40]. In
addition, we synthesized the corresponding positive control sequences containing phospho-threonine at the site of phosphorylation, ROCK-P1 and ROCK-P2 (Table 1).
Next, we measured the afﬁnity of each peptide construct for Mg2þ
(Fig. S1). Although positive control (phosphorylated) sequences are
expected to display stronger afﬁnities for Mg2þ, it is important to
quantify the difference in afﬁnities of substrate and product sequences such that Mg2þ concentrations can be appropriately
controlled for each construct [41]. Indeed, previous work from our
laboratory has demonstrated that this optimization step can provide a
dramatic enhancement in assay performance [40]. Using these
experimentally determined Mg2þ afﬁnities as a guide (Table 1), we
measured the increase in ﬂuorescence of each pair of product versus
substrate peptides under varying Mg2þ and ATP concentrations
(Table S2). Under optimized conditions, using 0.1 mM ATP, we were
able to obtain robust enhancements in probe ﬂuorescence in
response to phosphorylation (Table 1). Importantly, previous work
has demonstrated that the KM of ROCK2 for ATP is 1.4 mM [44], indicating that 0.1 mM ATP could be used for enzymatic assays without
severely interfering with the rate of substrate phosphorylation.
3.2. Evaluation of probe efﬁciency for ROCK2
Using the optimized Mg2þ and ATP concentrations identiﬁed
above, we interrogated the preference of ROCK2 for the position of
CSox within our probe sequences. Accordingly, we varied the
concentration of each substrate and measured the resulting rate of
product formation (Fig. 2). Interestingly, we observed substrate
inhibition for each probe design at increasing sensor concentrations. These results highlight the importance of fully characterizing
CSox-based activity probes, as the use of higher concentrations
(>10 mM) of the sensors described in this paper would lead to
diminished assay performance. Comparison of kcat/KM for each
sensor design indicated that ROCK-S1 was 188-fold more efﬁcient
for ROCK2. In particular, we observed a 33-fold decrease in probe
turnover by positioning CSox at the 2 position relative to the site
of phosphorylation in ROCK-S2. This indicates the sensitivity of
ROCK2 to CSox at this position. Using these experimental results as
a guide, we chose to employ ROCK-S1 at a concentration of 5 mM for
all subsequent experiments.
3.3. ROCK-S1 limit of detection for ROCK2
One signiﬁcant source of cost during HTS is recombinant kinase.
As a consequence, assays with low detection limits and high
reproducibility are desirable. To determine the sensitivity of ROCKS1, we measured sensor phosphorylation in the presence of
decreasing amounts of ROCK2. These experiments indicated the
ability to detect ROCK2 activity at concentrations as low as 10 pM
(Fig. 3). The trend line for this data is y ¼ 701.7x e 4.1 (R2 ¼ 0.9991),
where y is the average reaction slope in AFU/min and x is the
concentration of ROCK2 in nM. Moreover, these assays were highly
reproducible (Z’-factor ¼ 0.6 at 0.1 nM ROCK2), validating the use of
ROCK-S1 for HTS [45].
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Table 1
Sequences of ROCK activity probes.

3.4. ROCK-S1 can report on ROCK2 inhibition
As an initial test of whether ROCK-S1 could report on ROCK2
inhibition we assessed ROCK-S1 phosphorylation in the presence of
increasing concentrations of GSK429286, a well-characterized ATPcompetitive ROCK2 inhibitor [46]. As expected, we observed a

concentration dependent decrease in ROCK-S1 phosphorylation
that correlated with the literature IC50 value of 63 nM (Fig. 4) [47].
These data indicate the ability to straightforwardly monitor ROCK2
inhibition using ROCK-S1 in a 384-well format.
3.5. Optimization of HTS conditions
As a proof-of-principle for HTS using ROCK-S1 we chose to
screen a commercially available 78 compound library of kinase

Fig. 3. ROCK-S1 (5 mM) phosphorylation as a function of ROCK2 concentration.

Fig. 2. Kinetic parameters for ROCK-S1 (A) and ROCK-S2 (B) with ROCK2 (1 nM). Data
were ﬁt by using a modiﬁed form of the Michaelis-Menten equation [42], given in the
Experimental Section, in order to account for substrate inhibition.

Fig. 4. ROCK-S1 (5 mM) can report on the inhibition of ROCK2 (0.5 nM) by a wellcharacterized ATP-competitive inhibitor.

51
288

M.I. Kelly et al. / Analytica Chimica Acta 891 (2015) 284e290

inhibitors (Table S3). Importantly this library contains ﬁve known
inhibitors of ROCK2; fasudil [48], Y27632 [20], HA1100 [49], H89
[50], and GW5074 [51] as well as the broad spectrum inhibitor
Ro318220 [50]. Utilizing an automated robotics assay platform we
assessed the percent inhibition of each compound in our library at a
concentration of 10 mM in quadruplicate 384-well plate assays
(Fig. 5A). As expected, we observed >50% inhibition of ROCK2 by
fasudil, Y27632, HA1100, H89, GW5074, and Ro318220 (Fig. 5B).
Interestingly, we also observed >50% inhibition by two additional
inhibitors (PHA665752 [52] and IKK16 [53]) that to the best of our
knowledge have not been previously reported as ROCK2 inhibitors
in the primary literature (Fig. 5B). To further investigate the potency of these inhibitors we obtained IC50 values for each of these
scaffolds against ROCK2 (Fig. 6). Although these inhibitors displayed low mM to high nM potency for ROCK2 in the presence of
0.1 mM ATP, the relatively high concentrations of inhibitors
generally used during cell-based assays may lead to off-target
effects. As a consequence, the off-target effects of these inhibitors
could have important ramiﬁcations for the interpretation of
phenotypic assays. In the long term, the conditions outlined in this
work could be used to screen larger compound or fragment libraries for novel ROCK2 inhibitor scaffolds.
3.6. Selectivity of ROCK-S1
Another signiﬁcant advantage of CSox-based activity sensors is
the ability to selectively report on the activity of protein kinases in
heterogeneous biological samples such as cell lysates and tissue
homogenates [37,38,54,55]. However, in these complex samples
off-target activity can be observed from enzymes with overlapping
sequence speciﬁcity. In these situations off-target inhibitors have
been effectively employed to reduce potential false positive signal
in CSox-based assays [35,39,41,54]. As a ﬁrst step towards deﬁning
conditions for monitoring ROCK activity in heterogeneous samples
we assessed the selectivity of ROCK-S1 across a panel of protein
kinases including ROCK2, ROCK1, PKCa, PKA, and PAK. Importantly,
previous data demonstrated that the peptide sequence that serves
as a template for ROCK-S1 could act as a substrate for PKCa, PKA,
and PAK [15,43]. Our data demonstrates that our CSox-based probe,
ROCK-S1, could also be phosphorylated by PKA and PKCa (Fig. 7A).
We next investigated whether PKA and PKCa activities could be
suppressed with known inhibitors [35]. Accordingly we chose to
employ well-characterized PKA and PKCa inhibitors: PKItide, PKC
inhibitor peptide, calmidazolium, and GF109203X [35]. This inhibitor cocktail preserved a signiﬁcant portion, 58%, of ROCK2

Fig. 6. The indicated inhibitors were assayed against ROCK2 (0.25 nM) and inhibition
was monitored using ROCK-S1 (5 mM) in the presence of 0.1 mM ATP. Each scaffold
displays low mM to high nM inhibition of ROCK2.

Fig. 5. Proof-of-principle HTS for ROCK2 inhibitors. (A) Compounds (10 mM) were assayed against ROCK2 (1 nM) in the presence of 1 mM ATP. Percent inhibition was calculated
from quadruplicate assays. A complete compound list is given in Table S3. Position A1 corresponds to 10 mM GSK429286 (positive control) and position B1 represents no inhibitor
(negative control). (B) Eight compounds from the library displayed >50% ROCK2 inhibition. Six have been previously reported as ROCK2 inhibitors (grey bars) while two have, to the
best of our knowledge, not been previously reported to inhibit ROCK2 (red bars). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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activity (Fig. S2). However, the same inhibitor cocktail was capable
of completely abolishing the off-target phosphorylation of ROCK-S1
(Fig. 7B). Although our panel does not contain every possible offtarget enzyme present in cell lysates, this work represents an
important ﬁrst step towards deﬁning conditions for the analysis of
ROCK activity in complex biological samples such as cell lysates and
tissue homogenates. Future experiments will be aimed at identifying optimized inhibitor cocktails that have a reduced effect on
ROCK activity as well as accessing ROCK-S1 selectivity in cell
lysates.

289

a starting point for the development of ROCK2 inhibitors, although
the target speciﬁcity of these scaffolds would certainly need to be
optimized. In addition, we have deﬁned conditions that allow for
the selective monitoring of ROCK activity in the presence of potential off-target enzymes. The sensitivity of ROCK-S1, 10 pM
ROCK2, is on par with previously described Sox-based probes that
have been successfully utilized to detect kinase activity in unfractionated cell lysates [34,35,38,39,54]. Consequently, our laboratory
is currently investigating the use of ROCK-S1 to identify novel inhibitors of ROCK as well as interrogate ROCK activity perturbations
in HCC.
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Table S1
ESI-MS data for ROCK sensors.

Peptide
ROCK-S1
ROCK-P1
ROCK-S2
ROCK-P2

Calculated Mass Observed Mass
[M+xH]x+
[M+xH]x+
[M+2H]2+: 1202.9
1202.7
[M+2H]2+: 1243.0
1243.5
2+
[M+2H] : 1173.6
1173.9
[M+2H]2+: 1213.5
1213.9
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Table S2
Fold fluorescence enhancements of ROCK-S1 and ROCK-S2 constructs as a
function of Mg2+ and ATP concentrations.
Fold Fluorescence
Enhancementsa
0.1 mM
Peptide
Mg2+ (mM)
1.0 mM ATP
ATP
10
2.7
2.1
ROCK-P1
20
2.5
2.0
40
2.0
1.8
3.5
4.9
3.5
ROCK-P2
7.0
6.1
6.0
10.5
7.0
6.5
a
Fold fluorescence enhancements were determined as described
in Table 1.
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Table S3
Complete list of inhibitors used for HTS.
Identifier

Inhibitor (10 μM)

% Inhibition

Std.
Dev. (%)

A1

GSK 429286

100

0.12

A2

ML 9

22

0.82

A3

NH 124

11

0.49

A4

Fasudil

66

0.39

A5

GF109203x

31

1.00

A6

Genistein

4

0.26

A7

LY294002

3

0.63

A8

U0126

3

0.33

A9

PD98059

3

0.30

A10

Y-27632

80

0.22

B1

No Inhibitor Control

-1

1.12

B2

Olomoucine

16

0.83

B3

LFM-A13

14

0.62

B4

ZM 336372

10

0.60

B5

ZM 449829

7

0.20

B6

ZM 39923

9

0.55

B7

GW 5074

52

2.26

B8

PP1

5

0.36

B9

SB 203580

12

0.18

B10

(-)-Tarreic acid

8

0.36

C1

PP 2

22

1.82

C2

SU 4312

21

1.25

C3

SP 600125

3

2.90

C4

Purvalanol A

13

0.49

C5

Purvanol B

16

0.47

58

C6

KU 55933

8

0.37

C7

AG 490

28

1.42

C8

SB 216763

8

0.58

C9

SB 415286

14

0.46

C10

Arctigenin

7

0.70

D1

NSC 693868

28

2.14

D2

SB 239063

21

1.24

D3

SL 327

21

1.70

D4

Ro 31-8220

55

0.97

D5

Aminopurvalanol A

21

1.29

D6

API-2

11

0.85

D7

GW 441756

17

1.38

D8

GW 583340

22

0.92

D9

Ro 08-2750

44

0.59

D10

TBB

11

0.09

E1

hexabromocyclohexane

21

1.32

E2

HA 1100

68

0.37

E3

BIBX 1382

23

1.06

E4

CGP 53353

15

1.36

E5

Arcyriaflavin A

-9

1.02

E6

ZM 447439

20

0.86

E7

ER 27319

15

0.35

E8

ZM 323881

12

0.89

E9

ZM 306416

11

0.24

E10

IKK 16

81

0.87

F1

Ki 8751

24

1.39

F2

10-DEBC

21

0.79

F3

TPCA-1

22

0.53

F4

SB 218078

-26

6.40

59

F5

SB 202190

18

1.37

F6

PD 198306

13

0.67

F7

Ryuvidine

31

1.34

F8

IMD 0354

14

0.67

F9

CGK 733

11

0.20

F10

PHA 665752

85

0.85

G1

PD 407824

18

1.60

G2

LY 364974

17

1.08

G3

CGP 57380

16

1.21

G4

PQ 401

14

1.38

G5

PI 828

13

1.15

G6

NU 7026

12

0.90

G7

D4476

-23

5.10

G8

EO 1428

10

1.18

G9

H 89

76

1.28

G10

FPA 124

9

0.88

H1

GWn843682X

14

2.22

H2

Iressa

15

2.03

H3

SU 5416

10

1.73

H4

1-Napthyl PP1

8

1.81

H5

GSK 650394

19

2.23

H6

BIO

5

1.66

H7

SD 208

11

1.10

H8

Compound 401

6

1.28

H9

BI 78D3

8

1.21

H10

SC 514

8

1.05
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Figure S1

Fluorescence of ROCK-P1 (A), ROCK-S1 (B), ROCK-P2 (C), and ROCK-S2 (D)
as a function of Mg2+ concentration.
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Figure S2

A significant proportion (58%) of ROCK2 activity is retained in the presence (+) of
the inhibitor cocktail (0.4 μM PKItide, 4 μM PKC inhibitor peptide, 5 μM
GF109203X, and 4 μM calmidazolium) compared to reactions performed without
inhibitors (-).
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